Pal Shyama, Amin Prayag J, Sainis K B, Shankar Bhavani S
Immunology Section, Radiation Biology & Health Sciences Division, BioScience Group, Bhabha Atomic Research Centre, Modular Laboratories, Mumbai, 400085, India.
Cancer Microenviron. 2016 Dec;9(2-3):77-84. doi: 10.1007/s12307-016-0184-3. Epub 2016 Apr 23.
Apo2L/tumor necrosis factor (TNF)-α-related apoptosis-inducing ligand (TRAIL, TNFSF10) is an important cytokine in the tumor microenvironment and plays a major role in the balance of cell survival/death pathways. Bioinformatic analyses of 839 adenocarcinoma (AC) and 356 squamous cell lung carcinoma patient data (SCC) by cBioPortal (genomic analyses) shows that TRAIL expression leads to differential outcomes of disease free survival in AC and SCC. Oncomine datamining (transcript analyses) reveal that TRAIL is upregulated in 167 SCC as compared to 350 AC patients from six data sets. Genomic analyses using cBioPortal revealed high rates of KRAS mutation in AC accompanied by higher incidence of metastasis and increased amplifications of TRAIL gene in SCC. Bioinformatic analyses of an additional lung cancer patient database also showed that risk of disease progression was significantly increased with high TRAIL expression in AC (461 samples). In vitro studies demonstrated that TRAIL increased phosphorylation of ERK only in adenocarcinoma cell lines with mutant KRAS. This was associated with increased migration that was abrogated by MEK inhibitor PD98059. Effects of increased migration induced by TRAIL persisted even after exposure to ionizing radiation with suppression of DNA damage response. These results help understand the role of TRAIL signaling in metastasis which is essential to develop strategies to revert these signals into pro-apoptotic pathways.
Apo2L/肿瘤坏死因子(TNF)-α相关凋亡诱导配体(TRAIL,TNFSF10)是肿瘤微环境中的一种重要细胞因子,在细胞存活/死亡途径的平衡中起主要作用。通过cBioPortal(基因组分析)对839例腺癌(AC)和356例肺鳞状细胞癌患者数据(SCC)进行生物信息学分析表明,TRAIL表达导致AC和SCC中无病生存期的不同结果。Oncomine数据挖掘(转录分析)显示,与来自六个数据集的350例AC患者相比,167例SCC中TRAIL上调。使用cBioPortal进行的基因组分析显示,AC中KRAS突变率高,伴有更高的转移发生率,而SCC中TRAIL基因扩增增加。对另一个肺癌患者数据库的生物信息学分析还表明,AC(461个样本)中高TRAIL表达会显著增加疾病进展风险。体外研究表明,TRAIL仅在具有KRAS突变的腺癌细胞系中增加ERK的磷酸化。这与迁移增加相关,而MEK抑制剂PD98059可消除这种迁移增加。即使在暴露于抑制DNA损伤反应的电离辐射后,TRAIL诱导的迁移增加效应仍然存在。这些结果有助于理解TRAIL信号在转移中的作用,这对于制定将这些信号转化为促凋亡途径的策略至关重要。